Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

It will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" ...

The firm said it would focus resources on other late-stage programs after a Phase III study showed little survival benefit on first-line bemarituzumab.

The firm is expecting a preliminary data read out from the trial, which is already underway in the US, in the second half of this year.